<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047641</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0153</org_study_id>
    <secondary_id>NCI-2019-04730</secondary_id>
    <secondary_id>2017-0153</secondary_id>
    <nct_id>NCT04047641</nct_id>
  </id_info>
  <brief_title>Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome</brief_title>
  <official_title>A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well cladribine, idarubicin, cytarabine,&#xD;
      and quizartinib work in treating patients with acute myeloid leukemia or high-risk&#xD;
      myelodysplastic syndrome that is newly diagnosed, has come back (relapsed), or does not&#xD;
      respond to treatment (refractory). Drugs used in chemotherapy, such as cladribine,&#xD;
      idarubicin, and cytarabine, work in different ways to stop the growth of cancer cells, either&#xD;
      by killing the cells, by stopping them from dividing, or by stopping them from spreading.&#xD;
      Quizartinib may stop the growth of cancer cells by blocking some of the enzymes needed for&#xD;
      cell growth. Giving quizartinib with cladribine, idarubicin, and cytarabine may help to&#xD;
      control acute myeloid leukemia or high-risk myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the efficacy (defined as event-free survival) of quizartinib (AC220) in&#xD;
      combination with cladribine, idarubicin and cytarabine (ara-C) induction chemotherapy in&#xD;
      newly diagnosed or relapsed/refractory patients with high-risk acute myeloid leukemia (AML)&#xD;
      and high-risk myelodysplastic syndrome (MDS).&#xD;
&#xD;
      II. To determine the safety of the combination.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the overall survival and disease-free survival of patients treated with this&#xD;
      combination.&#xD;
&#xD;
      II. To investigate correlations of response to this combination with a 81-gene panel of gene&#xD;
      mutations both in patients with and without FLT3 mutations.&#xD;
&#xD;
      III. To identify individual treatment-resistant cell populations and their signaling state&#xD;
      that may relate to clinical outcomes using CyTOF (cytometry by time of flight) and single&#xD;
      cell sequencing.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      INDUCTION: Patients receive idarubicin intravenously (IV) over 1 hours on days 1-3,&#xD;
      cladribine IV over 1-2 hours on days 1-5, cytarabine IV over 3 hours on days 1-5 (or days 1-3&#xD;
      for patients over age 60), and quizartinib orally (PO) once daily (QD) on days 6-19.&#xD;
      Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      CONSOLIDATION: Patients who achieve complete response (CR) or CR with incomplete platelet&#xD;
      recovery (CRp) after Induction receive idarubicin IV over 1 hours on days 1-2, cladribine IV&#xD;
      over 1-2 hours on days 1-3, cytarabine IV over 3 hours on days 1-3, and quizartinib PO QD on&#xD;
      days 4-28. Treatment repeats every 28 days for up to 5 cycles in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      MAINTENANCE: Patients who achieve CR or CR with incomplete bone marrow recovery (CRi)/CR with&#xD;
      partial hematologic recovery (CRh) after Consolidation receive quizartinib PO QD on days&#xD;
      1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6-12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>From the date of start of treatment until event (resistance or relapse) or death, whichever occurred first, assessed up to 12 months</time_frame>
    <description>Will be estimate using the Kaplan-Meier method for each patient cohort. In addition, efficacy EFS will be analyzed in the intent to treat (ITT) population per cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Defined as any clinically significant treatment-related grade 3 or greater non-hematologic toxicity. Patient toxicity data will be summarized using frequency and percentages, by type, grade and relationship to the study drugs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be estimate using the Kaplan-Meier method for each patient cohort. In addition, efficacy OS will be analyzed in the ITT population per cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be estimate using the Kaplan-Meier method for each patient cohort. In addition, efficacy DFS will be analyzed in the ITT population per cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The rate of response will be estimated for each 28-gene panel of gene mutations for each patient cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of FLT3 ligand level</measure>
    <time_frame>Baseline up to 12 months</time_frame>
    <description>Will also explore the change of FLT3 ligand level before and after treatment using summary statistics, by patient cohort and by other subgroups (i.e. age).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the presence of other gene mutations</measure>
    <time_frame>Baseline up to 12 months</time_frame>
    <description>Will also explore the change in the presence of other gene mutations before and after treatment using summary statistics, by patient cohort and by other subgroups (i.e. age).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Blasts 20 Percent or More of Bone Marrow Nucleated Cells</condition>
  <condition>High Risk Myelodysplastic Syndrome</condition>
  <condition>Recurrent Acute Biphenotypic Leukemia</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Recurrent High Risk Myelodysplastic Syndrome</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Refractory High Risk Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (idarubicin, cladribine, cytarabine, quizartinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION: Patients receive idarubicin Intravenous over 1 hours on days 1-3, cladribine intravenous over 1-2 hours on days 1-5, cytarabine Intravenous over 3 hours on days 1-5 (or days 1-3 for patients over age 60), and quizartinib by mouth daily on days 6-19. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
CONSOLIDATION: Patients who achieve CR or CRp after Induction receive idarubicin Intravenous over 1 hours on days 1-2, cladribine Intravenous over 1-2 hours on days 1-3, cytarabine Intravenous over 3 hours on days 1-3, and quizartinib by mouth daily on days 4-28. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE: Patients who achieve CR or CRi/CRh after Consolidation receive quizartinib by mouth daily on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Given Intravenous</description>
    <arm_group_label>Treatment (idarubicin, cladribine, cytarabine, quizartinib)</arm_group_label>
    <other_name>2-CdA</other_name>
    <other_name>2CDA</other_name>
    <other_name>CdA</other_name>
    <other_name>Cladribina</other_name>
    <other_name>Leustat</other_name>
    <other_name>Leustatin</other_name>
    <other_name>Leustatine</other_name>
    <other_name>RWJ-26251</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given Intravenous</description>
    <arm_group_label>Treatment (idarubicin, cladribine, cytarabine, quizartinib)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Given Intravenous</description>
    <arm_group_label>Treatment (idarubicin, cladribine, cytarabine, quizartinib)</arm_group_label>
    <other_name>4-Demethoxydaunomycin</other_name>
    <other_name>4-demethoxydaunorubicin</other_name>
    <other_name>4-DMDR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quizartinib</intervention_name>
    <description>Given by mouth</description>
    <arm_group_label>Treatment (idarubicin, cladribine, cytarabine, quizartinib)</arm_group_label>
    <other_name>AC-220</other_name>
    <other_name>AC010220</other_name>
    <other_name>AC220</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of&#xD;
&#xD;
               -  AML (World Health Organization [WHO] classification definition of &gt;= 20% blasts,&#xD;
                  excluding Acute promyelocytic leukemia),&#xD;
&#xD;
               -  Acute biphenotypic leukemia or&#xD;
&#xD;
               -  High-risk MDS (&gt; 10% bone marrow blasts)&#xD;
&#xD;
          -  Frontline cohort: Patients aged 18 to 65 years&#xD;
&#xD;
          -  Relapse cohort: Patients aged &gt;=18 years old&#xD;
&#xD;
          -  Patients may be newly diagnosed (Frontline cohort) or with prior therapy (Relapsed&#xD;
             cohort) as follows:&#xD;
&#xD;
               -  For frontline cohort: Patients must be chemonaive, i.e., not have received any&#xD;
                  chemotherapy (except hydroxyurea [Hydrea] [no dose limit], tretinoin [atra] [no&#xD;
                  dose limit] or ara-C [one or two doses (max 2 gr/m^2 per dose)] for transient&#xD;
                  control of hyperleukocytosis) for AML or MDS. They may have received&#xD;
                  hypomethylating agents for prior MDS and transfusions, hematopoietic growth&#xD;
                  factors or vitamins. Temporary prior measures such as apheresis or Hydrea are&#xD;
                  allowed&#xD;
&#xD;
               -  For relapsed cohort: Patients with previously treated, relapsed or refractory&#xD;
                  AML, acute biphenotypic leukemia or high-risk MDS (&gt; 10% bone marrow blasts)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dl&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 mg/dL, unless increase is due to hemolysis or congenital&#xD;
             disorder&#xD;
&#xD;
          -  Transaminases (serum glutamate pyruvate transaminase [SGPT]) &lt; 2.5 x upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  Potassium, magnesium, and calcium (normalized for albumin) levels should be at least&#xD;
             within institutional normal limits&#xD;
&#xD;
          -  Ability to take oral medication&#xD;
&#xD;
          -  Ability to understand and provide signed informed consent&#xD;
&#xD;
          -  Baseline test of left ventricular ejection fraction &gt;= 50%&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test within 7 days&#xD;
&#xD;
          -  WOCBP must use appropriate method(s) of contraception such as oral contraceptive pills&#xD;
             (OCP), birth control shots, intrauterine device (IUD) etc. WOCBP should use an&#xD;
             adequate method to avoid pregnancy until 30 days after the last dose of&#xD;
             investigational drug. Men must agree not to father a child and agree to use a condom&#xD;
             if his partner is of child bearing potential. Women who are not of childbearing&#xD;
             potential (ie, who are postmenopausal or surgically sterile) as well as men with known&#xD;
             azoospermia do not require contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any coexisting medical condition that in the judgment of the treating physician is&#xD;
             likely to interfere with study procedures or results&#xD;
&#xD;
          -  Breastfeeding women&#xD;
&#xD;
          -  Patients with current active malignancies or any remission for &lt; 6 months, except&#xD;
             patients with carcinoma in situ or with non-melanoma skin cancer who may be in&#xD;
             remission for less than 6 months or have active disease&#xD;
&#xD;
          -  Active clinically serious and uncontrolled infection. Patients with recent infections&#xD;
             must have no temperature of &gt;= 101 degrees Fahrenheit (F) for at least 48 hours (hrs)&#xD;
&#xD;
          -  Patients with known significant impairment of gastrointestinal (GI) function or GI&#xD;
             disease that may significantly alter the absorption of quizartinib&#xD;
&#xD;
          -  Documented active central nervous system leukemia (patients with history of central&#xD;
             nervous system [CNS] leukemia without active disease are allowed)&#xD;
&#xD;
          -  Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV)&#xD;
             infection or active viral hepatitis&#xD;
&#xD;
          -  Patients who have had any major surgical procedure within 14 days of day 1&#xD;
&#xD;
          -  Impaired cardiac function including any of the following:&#xD;
&#xD;
               -  Screening electrocardiography (ECG) with a corrected QT (QTc) &gt; 450 msec. The QTc&#xD;
                  interval will be calculated by Fridericia's correction factor (QTcF) at screening&#xD;
                  and prior to the first dose of quizartinib (on day 6 during induction and day 4&#xD;
                  during consolidation). The QTcF will be derived from the average QTcF in&#xD;
                  triplicate. If QTcF &gt; 450 msec prior to the first dose, quizartinib will not be&#xD;
                  given until corrected&#xD;
&#xD;
               -  Patients with congenital long QT syndrome&#xD;
&#xD;
               -  Sustained ventricular tachycardia requiring medical intervention&#xD;
&#xD;
               -  Any history of clinically significant ventricular fibrillation or torsades de&#xD;
                  pointes&#xD;
&#xD;
               -  Known history of second or third degree heart block (may be eligible if the&#xD;
                  patient currently has a pacemaker)&#xD;
&#xD;
               -  Sustained heart rate of &lt; 50/minute on pre-entry ECG&#xD;
&#xD;
               -  Left bundle branch block&#xD;
&#xD;
               -  Right bundle branch block + left anterior hemiblock (bifascicular block)&#xD;
&#xD;
               -  Patients with myocardial infarction or unstable angina within 6 months prior to&#xD;
                  starting study drug&#xD;
&#xD;
               -  Congestive heart failure (CHF) New York (NY) Heart Association class III or IV&#xD;
&#xD;
               -  Atrial fibrillation documented within 2 weeks prior to first dose of study drug&#xD;
&#xD;
               -  Known family history of congenital long QT syndrome&#xD;
&#xD;
               -  Patients who are actively taking a strong CYP3A4 inducing medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Musa Yilmaz</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Musa Yilmaz</last_name>
    <phone>713-794-5783Z</phone>
    <email>myilmaz@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Musa Yilmaz</last_name>
      <phone>713-794-5783</phone>
    </contact>
    <investigator>
      <last_name>Musa Yilmaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>2-chloro-3'-deoxyadenosine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

